Lymphoma Trial, Recruiting (NCT07071051)

Lymphoma Trial, Recruiting NCT07071051 Sponsor: Mayo Clinic Condition: Lymphoma

Printed from Voxsanity (voxsanity.com.au) — NCT07071051 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Lymphoma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The person with the diagnosis must be between 2 and 21.5 years of age
They must have a confirmed diagnosis of acute lymphoblastic leukemia or lymphoblastic lymphoma (a type of blood cancer)
Their treatment plan must include a medication called Cal-PEG
A parent or guardian must have given formal consent for them to take part

Who may not be able to join:

People who have a pre-existing condition that affects how their blood clots
People who are known to have had a serious allergic reaction to asparaginase-based medications (a type of cancer drug)
People who have liver failure
People who have any ongoing or long-term illness known to affect blood clotting test results, such as nephrotic syndrome (a kidney condition) (confirm with trial site if unsure whether a condition qualifies)
People who are currently pregnant
People who have taken a blood-thinning medication in the 48 hours before the study blood sample is taken

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 16 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Madeleine B. O'Keefe, MD, Mayo Clinic in Rochester

Phone: 855-776-0015

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07071051

Sponsor: Mayo Clinic

Phase: Not Applicable

Status: Recruiting

Condition: Lymphoma

Trial contact: 855-776-0015

More information: https://clinicaltrials.gov/study/NCT07071051

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

The person with the diagnosis must be between 2 and 21.5 years of age
They must have a confirmed diagnosis of acute lymphoblastic leukemia or lymphoblastic lymphoma (a type of blood cancer)
Their treatment plan must include a medication called Cal-PEG
A parent or guardian must have given formal consent for them to take part

Who may not be able to join:

People who have a pre-existing condition that affects how their blood clots
People who are known to have had a serious allergic reaction to asparaginase-based medications (a type of cancer drug)
People who have liver failure
People who have any ongoing or long-term illness known to affect blood clotting test results, such as nephrotic syndrome (a kidney condition) (confirm with trial site if unsure whether a condition qualifies)
People who are currently pregnant
People who have taken a blood-thinning medication in the 48 hours before the study blood sample is taken

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 16 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Mayo Clinic

Registry

ClinicalTrials.gov

Start date

31 July 2025

Est. completion

31 December 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in coagulation - frequency; Change in coagulation - duration; Incidence of clinically relevant hematologic or thrombotic adverse events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov